2023 World Conference on Lung Cancer (Posters)-P1.24. Mortality Benefit of a 4-Protein Blood-Based Biomarker Panel for Lung Cancer

Pdf Summary

A recent study investigated the usefulness of integrating a panel of circulating protein biomarkers and a risk model based on individual characteristics to identify individuals at high risk of developing lethal lung cancer. The study aimed to address concerns about overdiagnosis associated with lung cancer screening. The US Preventive Services Task Force (USPSTF) currently recommends low-dose computed tomography (LDCT) screening for high-risk individuals between 55 and 80 years old with a smoking history of at least 30 pack-years. However, there are concerns about false-positive results and overdiagnosis. The study utilized a blood-based four-marker protein panel consisting of surfactant protein B, cancer antigen 125, carcinoembryonic antigen, and cytokeratin-19 fragment to assess the risk of lung cancer using pre-diagnostic sera from the Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial. The combination of the four-marker panel with the PLCOm2012 lung cancer risk model was found to better identify individuals at high risk of lung cancer who would benefit from screening compared to the USPSTF criteria. The study also evaluated the combined biomarker panel and risk model for its ability to predict lung cancer-specific mortality in the PLCO cohort. The results showed that the biomarker panel in combination with the risk model successfully identified individuals at high risk of lethal lung cancer. The study was supported by several grants from the National Institutes of Health and the Cancer Prevention & Research Institute of Texas. The authors expressed gratitude to the National Cancer Institute for providing access to data and specimens from the PLCO Cancer Screening Trial, as well as to the trial participants and staff members who made the study possible. The findings suggest that the blood-based biomarker panel and risk model could be valuable tools in identifying individuals at risk of death from lung cancer.

Asset Subtitle

Edwin Ostrin

Meta Tag

Speaker Edwin Ostrin

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

lung cancer

protein biomarkers

risk model

high risk

lethal lung cancer

overdiagnosis

lung cancer screening

low-dose computed tomography

false-positive results

blood-based biomarker panel